ArticleScientific reports2025
Evaluating third generation cervical Cancer intracavitary interstitial brachytherapy applicator efficacy and safety.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study evaluated the therapeutic effect of a third-generation intracavitary interstitial brachytherapy (IC-ISBT) technique combined with a source applicator template for locally advanced cervical cancer. This retrospective study examined 113 patients with stage IB3-IVB disease admitted to Sun Yat-sen University Cancer Center between January 2023 and January 2024. The high-risk clinical target area was defined based on residual tumor after external irradiation, and a third-generation IC-ISBT source donor template was developed. We compared the dosimetry and efficacy of the donor template (template interpolation group) and traditional manual implantation method (manual interpolation group) for treating cervical cancer. Regarding dosimetry coverage, the template group differed significantly from the freehand group, showing better target suitability (index) and dose coverage (V100%) (both P < 0.01). Simultaneously, the template protected the rectum and sigmoid colon, potentially reducing the high-dose areas (D0.1 cm³). However, the primary cervical remission rates did not differ significantly between groups. The study findings indicate that the design of the third-generation IC-ISBT applicator template was scientific and reasonable, especially for patients with large tumor volumes and late-stage disease. It is easy to operate and highly reproducible, proving beneficial for dose distribution and protecting surrounding key structures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.